Testing dilemmas in the clinic: Lessons learned from biomarker-based drug development

被引：0
|
作者：
van Waalwijk van Doorn-Khosrovani, Sahar Barjesteh [1 ,2 ]
Van Criekingen, Olga Kholmanskikh [3 ]
Koole, Simone [4 ]
Thomas, David M. [5 ]
Gelderblom, Hans [1 ]
机构：
[1] Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands
[2] CZ Hlth Insurance, Med Dept, Tilburg, Netherlands
[3] Belgian Fed Agcy Med & Hlth Prod FAMHP, Brussels, Belgium
[4] Zilveren Kruis, Med Advisory Dept, Zeist, Netherlands
[5] Univ New South Wales, Ctr Mol Oncol, Sydney, NSW, Australia
来源：
CANCER CELL | 2024年 / 42卷 / 06期
关键词：
HOMOLOGOUS RECOMBINATION DEFICIENCY;
D O I：
10.1016/j.ccell.2024.05.014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Various tests based on different biomarkers have been developed to identify the best candidates for poly(ADP-ribose) polymerase (PARP)-inhibitor therapy. However, due to the absence of harmonization regarding these complex biomarkers, along with various cutoff points and unknown spatial and temporal variations, it is difficult to define the clinical utility of each test and ensure uniformity in treatment decision-making. Here, we propose measures to align biomarker definitions and minimum analytical performance characteristics for diagnostics to ensure equitable and sustainable access to precision medicine.
引用
收藏
页码：923 / 929
页数：7
相关论文
共 50 条
  • [1] BIOMARKER-BASED DRUG DEVELOPMENT IN NSCLC
    Jaenne, P. A.
    ANNALS OF ONCOLOGY, 2012, 23 : 11 - 11
  • [2] Biomarker-Based Approach to α-Synucleinopathies: Lessons from Neuropathology
    Kovacs, Gabor G.
    Grinberg, Lea T.
    Halliday, Glenda
    Alafuzoff, Irina
    Dugger, Brittany N.
    Murayama, Shigeo
    Forrest, Shelley L.
    Martinez-Valbuena, Ivan
    Tanaka, Hidetomo
    Kon, Tomoya
    Yoshida, Koji
    Jaunmuktane, Zane
    Spina, Salvatore
    Nelson, Peter T.
    Gentleman, Steve
    Alegre-Abarrategui, Javier
    Serrano, Geidy E.
    Paes, Vitor Ribeiro
    Takao, Masaki
    Wakabayashi, Koichi
    Uchihara, Toshiki
    Yoshida, Mari
    Saito, Yuko
    Kofler, Julia
    Rodriguez, Roberta Diehl
    Gelpi, Ellen
    Attems, Johannes
    Crary, John F.
    Seeley, William W.
    Duda, John E.
    Keene, C. Dirk
    Woulfe, John
    Munoz, David
    Smith, Colin
    Lee, Edward B.
    Neumann, Manuela
    White, Charles L.
    Mckee, Ann C.
    Thal, Dietmar R.
    Jellinger, Kurt
    Ghetti, Bernardino
    Mackenzie, Ian R. A.
    Dickson, Dennis W.
    Beach, Thomas G.
    MOVEMENT DISORDERS, 2024,
  • [3] Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates
    Dowdy Jackson
    David Stover
    Pharmaceutical Research, 2015, 32 : 3458 - 3469
  • [4] Are there lessons to be learned from drug development that will accelerate the use of molecular imaging probes in the clinic?
    Eckelman, WC
    Rohatagi, S
    Krohn, KA
    Vera, DR
    NUCLEAR MEDICINE AND BIOLOGY, 2005, 32 (07) : 657 - 662
  • [5] Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates
    Jackson, Dowdy
    Stover, David
    PHARMACEUTICAL RESEARCH, 2015, 32 (11) : 3458 - 3469
  • [6] Lessons learned from drug design and development
    Parker, William
    PERSPECTIVES IN PUBLIC HEALTH, 2016, 136 (04) : 195 - 196
  • [7] Biomarker-guided drug development provides value for patients, payers and drug developers: lessons learned from 25 years in the biomarker industry
    Reese-Petersen, Alexander L.
    Breisnes, Helene W.
    Gabor, Daniel
    Ronnow, Sarah R.
    Manoel, Bruna
    Bajaj, Mayuur
    von Arenstorff, Claus S.
    Aighobahi, Elijah
    Vestermark, Rune
    Karsdal, Morten A.
    BIOMARKERS, 2024, 29 (04) : 222 - 232
  • [8] From Discovery to the Clinic: Lessons Learned
    Epstein, David L.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2012, 53 (05) : 2522 - 2522
  • [9] Biomarker-based diagnosis of preclinical Alzheimer disease: time for the clinic
    Sabbagh, Marwan N.
    DeCourt, Boris
    NATURE REVIEWS NEUROLOGY, 2023, 19 (02) : 71 - 72
  • [10] Biomarker-based diagnosis of preclinical Alzheimer disease: time for the clinic?
    Marwan N. Sabbagh
    Boris DeCourt
    Nature Reviews Neurology, 2023, 19 : 71 - 72
12345